Boston Scientific Corporation (BSX) fair value analysis

S&P 500 · Updated 2026-09-07

Boston Scientific Corporation is a medical device manufacturer that develops, produces, and markets products used in interventional medicine, including devices for cardiovascular, gastroenterology, urology, and oncology applications. The company operates globally across multiple regions including North America, Europe, and Asia-Pacific.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, BSX is trading at more than a 25% discount to estimated fair value.

BSX currently ranks #9 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $47.80
Sector: Healthcare
12-month range: $46.73–$101.01

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Momentum grade: B
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Strong
RSI zone: Neutral
52-week position: The bottom quarter of its range
DCF cross-check: Undervalued

What our data shows for BSX

Our model validated 17 trailing price-to-earnings windows for BSX, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $46.73–$101.01.
The 14-day relative strength index sits at a neutral 50.
3 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for BSX
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent BSX news

TickrTrends' derived news-sentiment signal for BSX is currently mixed, computed from recent coverage.

How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks? (finance.yahoo.com, 2026-09-02)
TickrTrends take: Boston Scientific operates in the Healthcare sector where valuations across medical device companies can vary significantly based on growth prospects and profitability metrics. The TickrTrends valuation model currently assesses BSX as undervalued, suggesting the market may not be fully pricing in factors such as competitive positioning or pipeline potential relative to peers in the medical device space. For valuation-focused readers, monitoring how BSX's operational performance tracks against comparable medical device manufacturers will be important to determine whether the undervalued assessment holds or if the market reprices the stock based on relative competitive dynamics.
BSX Looks 55.4% Undervalued on GF Value™ Amid Device Recall Concerns (gurufocus.com, 2026-08-26)
TickrTrends take: Boston Scientific Corporation trades at a significant discount to its GF Value assessment, suggesting the market has priced in considerable risk from recent device recall concerns. For valuation-focused investors, the key question becomes whether the company's underlying business fundamentals and long-term market position justify this discount or whether additional safety-related headwinds could pressure the stock further. The healthcare device sector often experiences temporary valuation dislocations following safety issues, making the sustainability of BSX's current discount an important metric to monitor alongside any regulatory developments and management guidance updates.
Boston Scientific Stock Falls 4% After Cyberattack Disrupts Global Operations (rttnews.com, 2026-08-26)
TickrTrends take: Boston Scientific's recent 4 percent stock decline following a cyberattack that disrupted global operations presents a notable disconnect with TickrTrends' current undervalued assessment of the company. A valuation-focused reader should monitor whether this operational disruption materially impacts the company's financial performance in upcoming quarters, as the extent and duration of the operational impact will be critical to determining if the undervalued designation remains justified. The Healthcare sector context is relevant here, as investors will be watching for any supply chain delays or revenue recognition issues that could emerge as the company works to restore normal operations.

What people are saying

Follow the BSX conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — TickrTrends' derived indicators for BSX show a shift toward undervaluation this week, with the DCF cross-check band moving from overvalued to undervalued status. This change reflects a recalibration of the company's valuation relative to its fundamental metrics within the Healthcare sector. The current assessment indicates that BSX is trading below levels suggested by discounted cash flow analysis.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is BSX stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), BSX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is BSX's TickrTrends verdict?

BSX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does BSX compare to other Healthcare stocks?

BSX ranks #9 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is BSX overbought or oversold?

BSX's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

BSX vs ADMA · BSX vs ALGN · BSX vs ANIP · BSX vs ASTH · BSX vs AZN